Literature DB >> 26065652

Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry.

Po-Lin Chiu1, George M Bou-Assaf2, Ekta Seth Chhabra2, Melissa G Chambers1, Robert T Peters2, John D Kulman2, Thomas Walz3.   

Abstract

Association with the D'D3 domain of von Willebrand factor (VWF) stabilizes factor VIII (FVIII) in the circulation and maintains it at a level sufficient to prevent spontaneous bleeding. We used negative-stain electron microscopy (EM) to visualize complexes of FVIII with dimeric and monomeric forms of the D'D3 domain. The EM averages show that FVIII interacts with the D'D3 domain primarily through its C1 domain, with the C2 domain providing a secondary attachment site. Hydrogen-deuterium exchange mass spectrometry corroborated the importance of the C1 domain in D'D3 binding and implicates additional surface regions on FVIII in the interaction. Together, our results establish that the C1 domain is the major binding site on FVIII for VWF, reiterate the importance of the a3 acidic peptide in VWF binding, and suggest that the A3 and C2 domains play ancillary roles in this interaction.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26065652      PMCID: PMC4543227          DOI: 10.1182/blood-2015-04-641688

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies.

Authors:  Damian Houde; Steven A Berkowitz; John R Engen
Journal:  J Pharm Sci       Date:  2010-12-29       Impact factor: 3.534

2.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

3.  Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake.

Authors:  Esther Bloem; Maartje van den Biggelaar; Aleksandra Wroblewska; Jan Voorberg; Johan H Faber; Marianne Kjalke; Henning R Stennicke; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2013-09-05       Impact factor: 5.157

4.  Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.

Authors:  H J Weiss; I I Sussman; L W Hoyer
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

5.  A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor.

Authors:  M Jacquemin; R Lavend'homme; A Benhida; B Vanzieleghem; R d'Oiron; J M Lavergne; H H Brackmann; R Schwaab; T VandenDriessche; M K Chuah; M Hoylaerts; J G Gilles; K Peerlinck; J Vermylen; J M Saint-Remy
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

6.  A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.

Authors:  M Jacquemin; A Benhida; K Peerlinck; B Desqueper; L Vander Elst; R Lavend'homme; R d'Oiron; R Schwaab; M Bakkus; K Thielemans; J G Gilles; J Vermylen; J M Saint-Remy
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

7.  A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.

Authors:  J E Sadler
Journal:  Thromb Haemost       Date:  1994-04       Impact factor: 5.249

8.  The tertiary structure and domain organization of coagulation factor VIII.

Authors:  Betty W Shen; Paul Clint Spiegel; Chong-Hwan Chang; Jae-Wook Huh; Jung-Sik Lee; Jeanman Kim; Young-Ho Kim; Barry L Stoddard
Journal:  Blood       Date:  2007-10-26       Impact factor: 22.113

9.  The photolysis of disulfide bonds in IgG1 and IgG2 leads to selective intramolecular hydrogen transfer reactions of cysteine Thiyl radicals, probed by covalent H/D exchange and RPLC-MS/MS analysis.

Authors:  Shuxia Zhou; Olivier Mozziconacci; Bruce A Kerwin; Christian Schöneich
Journal:  Pharm Res       Date:  2013-01-11       Impact factor: 4.200

10.  Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.

Authors:  R T Peters; G Toby; Q Lu; T Liu; J D Kulman; S C Low; A J Bitonti; G F Pierce
Journal:  J Thromb Haemost       Date:  2013-01       Impact factor: 5.824

View more
  23 in total

1.  The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.

Authors:  Bagirath Gangadharan; Mathieu Ing; Sandrine Delignat; Ivan Peyron; Maud Teyssandier; Srinivas V Kaveri; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

2.  Molecular coevolution of coagulation factor VIII and von Willebrand factor.

Authors:  Philip M Zakas; Christopher W Coyle; Anja Brehm; Marion Bayer; Barbara Solecka-Witulska; Caelan E Radford; Christine Brown; Kate Nesbitt; Courtney Dwyer; Christoph Kannicht; H Trent Spencer; Eric A Gaucher; Christopher B Doering; David Lillicrap
Journal:  Blood Adv       Date:  2021-02-09

3.  Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

Authors:  Joerg Kahle; Aleksander Orlowski; Diana Stichel; John F Healey; Ernest T Parker; Marc Jacquemin; Manuela Krause; Andreas Tiede; Dirk Schwabe; Pete Lollar; Christoph Königs
Journal:  Blood       Date:  2017-05-15       Impact factor: 22.113

4.  FVIII-VWF dos-à-dos.

Authors:  Sriram Krishnaswamy
Journal:  Blood       Date:  2015-08-20       Impact factor: 22.113

Review 5.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

6.  Epitope characterization of anti-JAM-A antibodies using orthogonal mass spectrometry and surface plasmon resonance approaches.

Authors:  Guillaume Terral; Thierry Champion; François Debaene; Olivier Colas; Maxime Bourguet; Elsa Wagner-Rousset; Nathalie Corvaia; Alain Beck; Sarah Cianferani
Journal:  MAbs       Date:  2017-09-21       Impact factor: 5.857

7.  The von Willebrand factor D'D3 assembly and structural principles for factor VIII binding and concatemer biogenesis.

Authors:  Xianchi Dong; Nina C Leksa; Ekta Seth Chhabra; Joseph W Arndt; Qi Lu; Kevin E Knockenhauer; Robert T Peters; Timothy A Springer
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

8.  Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.

Authors:  Wojciech Jankowski; Yara Park; Joseph McGill; Eugene Maraskovsky; Marco Hofmann; Vincent P Diego; Bernadette W Luu; Tom E Howard; Roberta Kellerman; Nigel S Key; Zuben E Sauna
Journal:  Blood Adv       Date:  2019-05-14

9.  High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

Authors:  Glaivy Batsuli; Wei Deng; John F Healey; Ernest T Parker; W Hunter Baldwin; Courtney Cox; Brenda Nguyen; Joerg Kahle; Christoph Königs; Renhao Li; Pete Lollar; Shannon L Meeks
Journal:  Blood       Date:  2016-07-05       Impact factor: 22.113

10.  FVIII half-life extension by coadministration of a D'D3 albumin fusion protein in mice, rabbits, rats, and monkeys.

Authors:  Sabine Pestel; Hans-Wilhelm Beltz; Philipp Claar; Holger Lind; Marcel Mischnik; Elmar Raquet; Arna Andrews; Jason Simmonds; Vesna Tomasetig; Steven K Dower; Anna Tjärnlund-Wolf; Stefan Schulte; Peter M Schmidt; Thomas Weimer
Journal:  Blood Adv       Date:  2020-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.